MedImmune and Crucell jointly develop new antibodies for the treatment and prevention of hospital-acquired bacterial infection

17-Oct-2007

MedImmune and Crucell N.V. announced that they have entered into an exclusive license and research collaboration to further develop and commercialize one of Crucell's panels of bacterial antibodies primarily for the treatment and prevention of hospital-acquired bacterial infection.

Under the agreement, MedImmune is to provide Crucell certain upfront, annual and milestone payments potentially exceeding US$ 40 million, plus research and development (R&D) funding and an undisclosed royalty on product sales.

Under the terms of the agreement, Crucell has granted MedImmune an exclusive license to research, develop and commercialize antibodies within one of its MAbstract®-technology programs. In addition MedImmune will have access to Crucell's antibody capabilities for further R&D.

The partnership combines Crucell's unique antibody discovery, research and development capabilities with MedImmune's expertise in clinical development and commercialization of anti-infective antibodies.

In 2005, Crucell announced the initiation of several new antibody discovery programs in the field of hospital-acquired infections. Under the terms of the license agreement announced today, Crucell has now entered into a partnership with MedImmune for one of these programs. Crucell has discovered and developed these unique anti-bacterial antibodies using its proprietary MAbstract® technology.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous